NCT07503444
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 40 → 46 locations
- Minor Trial sites expanded: 32 → 40 locations
- Minor Study sites: 32 to 33
- Minor Trial sites expanded: 23 → 32 locations
- Notable Eligibility criteria expanded, about 22 words
- Trial sites expanded: 18 → 23 locations
- Secondary endpoints: details revised at 17 of 17 entries
Notable Primary completion pushed from Aug 1, 2028 to Feb 6, 2029v8 Show 6 more changesShow less
- Recruitment opened
- Eligibility criteria expanded, about 2 words
- Trial sites expanded: 10 → 18 locations
- Study completion pushed from Nov 15, 2030 to Aug 29, 2031
- Start date changed from estimate of Jun 30, 2026 to Jul 14, 2026
- Secondary endpoints: 10 to 17
- Minor Study sites: 9 to 10v7
- Minor Trial sites expanded: 5 → 9 locationsv6
- Notable Start date: May 31, 2026 to Jun 30, 2026v5
- Minor Study sites: 4 to 5v4
- Minor Study sites: 2 to 4v3
- Notable Start date: Mar 31, 2026 to May 31, 2026
- Study sites: 0 to 2
- Secondary endpoints revised (10)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (17)
Show 12 moreShow less
Arms and interventions
Participants will receive fenfluramine hydrochloride for 14 weeks in a double-blind period (including titration and maintenance), followed by a 2-week double-blind transition period. This is followed by a 52-week open-label treatment period. Participants may continue treatment until alternative access is available. Those who discontinue without continued access will undergo an 8-day taper and a 26-week follow-up.
Participants will receive a matching placebo for 14 weeks in a double-blind period (including titration and maintenance). After this period, they transition into a 2-week double-blind period with fenfluramine hydrochloride, followed by a 52-week open-label treatment period. Participants may continue treatment until alternative access is available. Those who discontinue without continued access will undergo an 8-day taper and a 26-week follow-up.
Drugs: fenfluramine hydrochloride
Other: Placebo
Sites
46 sites in 13 countries
United States 8, Italy 7, Japan 6, France 5, Spain 5, United Kingdom 3, Belgium 2, China 2, Georgia 2, Hungary 2, Poland 2, Germany 1, Israel 1